Skip to content

D&A at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$594M-41.3%
Ethos Technologies, Inc.
 logo
Ethos Technologies, Inc. LIFE
$162K-3.0%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$672K+25.6%
LQD
Liquidia CorporationLQDA
$497K+10.2%
United Therapeutics logo
United TherapeuticsUTHR
$22.6M+14.1%
Tenet Healthcare logo
Tenet HealthcareTHC
$229M+11.2%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: RNTX’s 10-Q, filed August 14, 2025, on SEC EDGAR. View the filing →

Ask your AI about RNTX's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's D&A?
RNTX (RNTX) reported D&A of $1K in Q2 2025.
How has RNTX's D&A changed year-over-year?
RNTX's D&A decreased by 75.0% year-over-year, from $4K to $1K.
What is the long-term trend for RNTX's D&A?
Over 2 years (2021 to 2023), RNTX's D&A has grown at a -0.8% compound annual growth rate (CAGR), from $121K to $119K.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.